The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.
 
Rino S. Seedor
No Relationships to Disclose
 
Marlana Orloff
Consulting or Advisory Role - Immunocore
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
J. Silvio Gutkind
Employment - Domain Therapeutics; Oncoceutics; Vividion Therapeutics
Stock and Other Ownership Interests - Vividion Therapeutics
Research Funding - Dracen; Kura Oncology; Revolution Medicines
 
Andrew E. Aplin
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Patent Number 9880150
 
Mizue Terai
Research Funding - IDEAYA Biosciences (Inst); Prelude Therapeutics (Inst)
 
Erin Sharpe-Mills
No Relationships to Disclose
 
Haley Klose
No Relationships to Disclose
 
Michael J. Mastrangelo
No Relationships to Disclose
 
Takami Sato
Consulting or Advisory Role - Castle Biosciences; Immunocore
Research Funding - Immunocore (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Castle Biosciences